日本 iPS 再生医疗和条件期限承认插图
Japan Frontier Technology, Regenerative Medicine

Japan’s Regenerative Medicine Enters the Stage of Clinical Implementation: iPS Approvals, Conditional and Time-Limited Approval, and the Boundaries of Patient Expectations

/

从 AMCHEPRY、Heartseed HS-005 和 PMDA 条件期限承认制度，看日本 iPS 再生医疗为什么值得关注，也为什么必须谨慎解读。